Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor-Reference-Cited by-同舟云学术

Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor

Published:2022-11-01 Issue:21 Volume:61 Page:3239-3243
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Konta Yusuke¹,Saito Eiichiro¹,Sato Koji¹,Furuta Kyohei¹,Miyauchi Kenichiro¹,Furukawa Akiko¹,Sato Hiroshi²,Yamamoto Tae³

Affiliation:

1. Department of Internal Medicine, Sendai City Hospital, Japan

2. Department of Nephrology, JR Sendai Hospital, Japan

3. Division of Nephrology, Endocrinology and Vascular Medicine, and Research Division of Chronic Kidney Disease and Dialysis Treatment, Tohoku University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/21/61_9011-21/_pdf

Reference18 articles.

1. 1. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1: 140-151, 2013.

2. 2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.

3. 3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.

4. 4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347-357, 2019.

5. 5. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323-334, 2016.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alogliptina y nefritis tubulointersticial: una complicación potencial;Nefrología;2024-09

2. Dapagliflozin-induced drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Followed By Acute Interstitial Nephritis (AIN): A Case Report;Internal Medicine;2024

3. Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure;Expert Review of Cardiovascular Therapy;2023-11-02

4. Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis;Internal Medicine;2023-03-01

5. Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis;Internal Medicine;2023-03-01